The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
Chronic kidney disease affects over one in seven Americans, but new drugs like Ozempic are changing the game. GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone offer additive benefits beyond traditional RAS inhibitors, potentially halting or reversing progression. Experts like Maarten Taal hail them as game-changers for kidney health.
India's GLP-1 and weight-loss drug market is set for explosive growth, expanding fivefold to ₹5,000 crore by 2030, according to CareEdge Ratings. Semaglutide's patent expiry will trigger sharp price cuts, boosting access amid surging demand from type 2 diabetes patients. However, generic makers face patent battles, manufacturing hurdles, and safety scrutiny.
Kelly Osbourne's black sequined mini dress at the BRIT Awards turned heads for more than fashion—her slimmer frame ignited Ozempic speculation. Joined by Demi Moore, Emma Stone, and others at 2026 red carpets, these stars' dramatic weight loss sparked debates on 'Ozempic face' and Hollywood beauty standards. Discover the details and medical context.
Melissa McCarthy turned heads at the 2026 Oscars in a stunning gown, but her noticeably slimmer face reignited Ozempic rumors. Side-by-side pics with her 2012 Oscars appearance make the change crystal clear. Onstage, she even poked fun at the speculation during a Bridesmaids reunion.
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
Revolutionary GLP-1 medications like Ozempic are helping millions shed pounds quickly, but a new study shows significant muscle loss is a downside. Experts warn that up to 40% of weight lost can be lean tissue, especially with rapid drops. Here's how to protect your muscle while benefiting from these drugs.
